Comparative Pharmacology
Head-to-head clinical analysis: AZILECT versus XADAGO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZILECT versus XADAGO.
AZILECT vs XADAGO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversible selective inhibitor of monoamine oxidase type B (MAO-B), which inhibits the metabolism of dopamine in the brain, increasing dopaminergic activity.
XADAGO (safinamide) is a selective, reversible monoamine oxidase B (MAO-B) inhibitor. It also blocks voltage-dependent sodium and calcium channels, and modulates glutamate release. The MAO-B inhibition increases dopamine levels in the striatum, while the other actions may provide neuroprotective and symptomatic benefits.
1 mg orally once daily
XADAGO (safinamide) 50 mg orally once daily, increased to 100 mg orally once daily based on tolerability and efficacy; take at the same time each day.
None Documented
None Documented
Terminal elimination half-life of rasagiline is approximately 3-4 hours; however, due to irreversible MAO-B inhibition, the pharmacological effect lasts longer than the elimination half-life.
Terminal elimination half-life is approximately 20-25 hours, supporting once-daily dosing.
Renal (approximately 60% of dose as metabolites, <1% unchanged); fecal (about 20%); small amount exhaled as CO2. Metabolites primarily excreted via urine.
Primarily renal (approximately 70% as unchanged drug and major metabolite O-desmethylsafinamide) and fecal (approximately 30%).
Category C
Category C
MAO-B Inhibitor
MAO-B Inhibitor